(59 days)
No
The summary describes post-processing software for MR datasets using mathematical and statistical analysis, visualization, and workflow tools, but does not mention AI or ML.
No.
The device is described as post-processing software that assists radiologists in analyzing MR datasets and arriving at a diagnosis. It does not directly provide therapy or treatment.
Yes
Explanation: The "Intended Use / Indications for Use" section explicitly states that the device "serves as a workflow roadmap tool that organizes and guides the radiologist through the series of sequential tasks that must be performed in order to arrive at a diagnosis" and that "In the hands of a trained physician the information provided by the data analysis could yield information that may assist in the interpretation of dynamic and non-dynamic MR studies." This indicates its role in assisting diagnosis.
Yes
The device description explicitly states that the VersaVue Enterprise Suite "consists of the following two products; each product in turn incorporates individual modules," and then lists "MR Analysis Server Software" and "VersaVue Enterprise Workstation Software." There is no mention of any accompanying hardware components being part of the device itself. While it processes data from an MRI machine (hardware), the device being cleared is the software suite.
Based on the provided text, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In Vitro Diagnostics are devices intended for use in the collection, preparation, and examination of specimens taken from the human body (such as blood, urine, or tissue) to provide information for the diagnosis, treatment, or prevention of disease.
- Device Function: The VersaVue™ Enterprise Suite is a post-processing software package that analyzes MR datasets (images). It does not interact with or analyze biological specimens taken from the body. Its purpose is to assist in the interpretation of medical images generated by an MRI scanner.
- Intended Use: The intended use clearly states it's for analyzing MR datasets to assist in the interpretation of dynamic and non-dynamic MR studies and to guide the radiologist through the diagnostic workflow. This is image analysis and workflow management, not in vitro testing.
The device is a medical device, specifically a software medical device for image analysis and workflow support, but it does not fit the definition of an In Vitro Diagnostic.
N/A
Intended Use / Indications for Use
The VersaVue Enterprise Suite consists of the MR Analysis Server software and the VersaVue Enterprise Workstation software.
The MR Analysis Server software, which includes the SpectraLook®, VividLook® and OmniLook modules is intended to be used as a post-processing software package designed to provide a reliable means for analyzing MR datasets. The software facilitates the analysis of dynamic and non-dynamic MR datasets to provide study review and additional mathematical and/or statistical analysis. The resulting analysis can be displayed in a variety of formats, including parametric images overlaid onto source MRI images.
The VersaVue Enterprise Workstation software is intended for use in conjunction with the MR Analysis Server software and facilitates the analysis and presentation of datasets generated by the MR Analysis Server software and incorporates the following functions: Region of Interest (ROI) curve, Pixel of Interest (POI) curve, Report Card, Volume Calculation, Statistical Analysis, 3-D visualization of image series, and DICOM reporting, among other capabilities.
The VersaVue Enterprise Suite serves as a workflow roadmap tool that organizes and guides the radiologist through the series of sequential tasks that must be performed in order to arrive at a diagnosis. The specific configuration of product features drives the Suite's underlying workflow solution for lesion characterization and reporting. This inherent workflow regimen integrates easily into the radiologist's existing departmental workflow and can be adapted to fit the needs of each user, thereby streamlining diagnosis. In the hands of a trained physician the information provided by the data analysis could yield information that may assist in the interpretation of dynamic and non-dynamic MR studies.
Product codes (comma separated list FDA assigned to the subject device)
90 LLZ
Device Description
The VersaVue Enterprise Suite is intended for post-processing of MR datasets to provide a reliable means for visualizing MR datasets and supports the evaluation of dynamic and non-dynamic MRI datasets. It is also designed to provide study review and mathematical. and/or statistical analysis. The VersaVue Enterprise Suite serves as a workflow roadmap tool that organizes and guides the radiologist through the series of sequential tasks that must be performed in order to arrive at a diagnosis.
This is the same intended use for the previously cleared 3TP predicate devices.
The VersaVue Enterprise Suite consists of the following two products; each product in turn incorporates individual modules:
- MR Analysis Server Software_consists of:
- SpectraLook, for Breast MR analysis .
- VividLook, for Prostate MR analysis .
- OmniLook, for analysis of other MR datasets .
-
- VersaVue Enterprise Workstation Software
- PrecisionPoint, for MR Breast Interventional Planning (K090223) o
The MR Analysis Server Software is intended to be used as a post-processing software package designed to provide a reliable means for visualizing MR data. The data analysis supports the evaluation of dynamic and non-dynamic MR datasets. The MR Analysis Server software also analyzes contrast enhanced magnetic resonance imaging (DCE-MRI) studies. The resulting information can be displayed in a variety of formats, including a parametric image overlaid onto source MR images. In the hands of a trained. physician the information provided by the software yields information that may assist in the interpretation of dynamic contrast enhanced studies.
The VersaVue Enterprise Workstation Software is intended for use in conjunction with SpectraLook, VividLook and OmniLook MR post-processing analysis software to provide study review and additional mathematical and/or statistical analysis. The Workstation software does not change the SpectraLook, VividLook or OmniLook software algorithm or the image series produced by the algorithm. It supports the analysis and presentation of the original MR datasets and the results generated by the software algorithm and incorporates the following functions: Region of Interest (ROI) curve, Pixel of Interest (POI) curve, Report Card, Volume Calculation, Statistical Analysis, 3-D visualization of image series, and DICOM reporting, among other capabilities.
The Workstation software also works with iCAD's PrecisionPoint Breast Interventional biopsy software. The Breast Interventional Planning Software cleared under K090223 integrates intervention planning ability into the existing iCAD viewing workstation, allowing physicians to read images followed by subsequent planning of MRI-guided percutaneous breast biopsies and other interventional procedures. Biopsy planning, puidance and all necessary documentation are generated through the same Workstation interface.
Mentions image processing
Yes
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Magnetic Resonance Imaging (MRI)
Anatomical Site
Breast, Prostate, other MR datasets
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Radiologist, trained physician; Departmental workflow
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Validation testing was performed according to a Software System Test Plan. All performance, functional and system requirement were met. Test data was used that met the requirements to validate system performance.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
K031350, K050862, K070244, K111311
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 892.2050 Medical image management and processing system.
(a)
Identification. A medical image management and processing system is a device that provides one or more capabilities relating to the review and digital processing of medical images for the purposes of interpretation by a trained practitioner of disease detection, diagnosis, or patient management. The software components may provide advanced or complex image processing functions for image manipulation, enhancement, or quantification that are intended for use in the interpretation and analysis of medical images. Advanced image manipulation functions may include image segmentation, multimodality image registration, or 3D visualization. Complex quantitative functions may include semi-automated measurements or time-series measurements.(b)
Classification. Class II (special controls; voluntary standards—Digital Imaging and Communications in Medicine (DICOM) Std., Joint Photographic Experts Group (JPEG) Std., Society of Motion Picture and Television Engineers (SMPTE) Test Pattern).
0
Special 510(k) Device Modificatio May 21, 2012
SECTION 6: 510(K) Summary
510(k) OWNER and MANUEACTURER:
iCAD Inc. 98 Spit Brook Road, Suite 100 Nashua, NH 03062 T: 603-882-5200 Ext 7308 F: 603- 880-3843
Registered Establishment Number: 1225671
NAME OF CONTACT:
Michael A. Patz Senior Director, Clinical Affairs
DATE SUMMARY PREPARED:
May 21, 2012
TRADE NAME:
VersaVue Enterprise Suite
COMMON NAME:
MRI Analysis and Advanced Visualization Software
CLASSIFICATION:
CLASS II
CLASSIFICATION NAME:
Picture Archiving and Communications System
CRF CLASSIFICATION:
21 CFR 892.2050
PRODUCT CODE:
90 LLZ
JUL 20 2012
Page 13 of 91
1
SECTION 6: 510(K) Summary (con't)
Legally Marketed Devices to Which Substantial Equivalence is Claimed 6.1
iCAD's Versa Vue Enterprise Suite consists of the MR Analysis Server Software and the Versa Vue Enterprise Workstation Software, these two components are substantially equivalent to the following legally marketed predicate devices that post-process and display data based on magnetic resonance imaging (MRI) datasets.
| Device Name | Software
Purpose | Manufacturer | 510(k) Reference # | Concurrence Date |
|---------------------|---------------------------------------------------------------|--------------------------------------------------|--------------------|------------------|
| 3TP Software Option | MR image
analysis | iCAD, Inc.
(Formally
CAD Sciences,
Inc. | K031350 | 06/23/2003 |
| 3TP Workspace | MR image
analysis | iCAD, Inc.
(Formally
CAD Sciences,
Inc. | K050862 | 07/25/2005 |
| Aegis | Auto contrast
arrival | Sentinelle/
Hologic, Inc. | K070244 | 02/09/2007 |
| Segasist P-AC 1.0 | Segmentation
assistant for
prostate-auto-
contouring | Segasist
Technologies | K111311 | 10/17/11 |
TABLE 1: Legally Marketed Predicate Devices
Device Description 6.2
The VersaVue Enterprise Suite is intended for post-processing of MR datasets to provide a reliable means for visualizing MR datasets and supports the evaluation of dynamic and non-dynamic MRI datasets. It is also designed to provide study review and mathematical. and/or statistical analysis. The VersaVue Enterprise Suite serves as a workflow roadmap tool that organizes and guides the radiologist through the series of sequential tasks that must be performed in order to arrive at a diagnosis.
This is the same intended use for the previously cleared 3TP predicate devices.
The VersaVue Enterprise Suite consists of the following two products; each product in turn incorporates individual modules:
- MR Analysis Server Software_consists of:
- SpectraLook, for Breast MR analysis .
2
Special 510(k) Device Modificatio May 21, 2012
- VividLook, for Prostate MR analysis .
- OmniLook, for analysis of other MR datasets .
-
- VersaVue Enterprise Workstation Software
- PrecisionPoint, for MR Breast Interventional Planning (K090223) o
The MR Analysis Server Software is intended to be used as a post-processing software package designed to provide a reliable means for visualizing MR data. The data analysis supports the evaluation of dynamic and non-dynamic MR datasets. The MR Analysis Server software also analyzes contrast enhanced magnetic resonance imaging (DCE-MRI) studies. The resulting information can be displayed in a variety of formats, including a parametric image overlaid onto source MR images. In the hands of a trained. physician the information provided by the software yields information that may assist in the interpretation of dynamic contrast enhanced studies.
The VersaVue Enterprise Workstation Software is intended for use in conjunction with SpectraLook, VividLook and OmniLook MR post-processing analysis software to provide study review and additional mathematical and/or statistical analysis. The Workstation software does not change the SpectraLook, VividLook or OmniLook software algorithm or the image series produced by the algorithm. It supports the analysis and presentation of the original MR datasets and the results generated by the software algorithm and incorporates the following functions: Region of Interest (ROI) curve, Pixel of Interest (POI) curve, Report Card, Volume Calculation, Statistical Analysis, 3-D visualization of image series, and DICOM reporting, among other capabilities.
The Workstation software also works with iCAD's PrecisionPoint Breast Interventional biopsy software. The Breast Interventional Planning Software cleared under K090223 integrates intervention planning ability into the existing iCAD viewing workstation, allowing physicians to read images followed by subsequent planning of MRI-guided percutaneous breast biopsies and other interventional procedures. Biopsy planning, puidance and all necessary documentation are generated through the same Workstation interface.
"Indications for Use" 6.3
Indications for Use:
The VersaVue™ Enterprise Suite consists of the MR Analysis Server software and the VersaVue Enterprise Workstation software.
The MR Analysis Server software, which includes the SpectraLook®, VividLook® and The MIC I marysis be researce to be used as a post-processing software package designed to provide a reliable means for analyzing MR datasets. The software facilitates the analysis of
3
$\rho^{4}/_{5}$
dynamic and non-dynamic MR datasets to provide study review and additional mathematical and/or statistical analysis. The resulting analysis can be displayed in a variety of formats, including parametric images overlaid onto source MRI images.
The VersaVue Enterprise Workstation software is intended for use in conjunction with the MR Analysis Server software and facilitates the analysis and presentation of datasets generated by the MR Analysis Server software and incorporates the following functions: Region of Interest (ROI) curve, Pixel of Interest (POI) curve, Report Card, Volume Calculation, Statistical Analysis, 3-D visualization of image series, and DICOM reporting, among other capabilities.
The VersaVue Enterprise Suite serves as a workflow roadmap tool that organizes and guides the radiologist through the series of sequential tasks that must be performed in order to arrive at a diagnosis. The specific configuration of product features drives the Suite's underlying workflow solution for lesion characterization and reporting. This inherent workflow regimen integrates easily into the radiologist's existing departmental workflow and can be adapted to fit the needs of each user. thereby streamlining diagnosis. In the hands of a trained physician the information. provided by the data analysis could yield information that may assist in the interpretation of dynamic and non-dynamic MR studies.
Summary of Changes 6.4
The iCAD VersaVue Enterprise Suite has the same intended use, fundamental scientific technology, and characteristics as the previously cleared predicate devices. However, the following features have been added as outlined below:
| Feature | Predicate Devices | Change to Intended Use | Change to Fundamental Scientific Technology | ||
|---|---|---|---|---|---|
| 3TP Software Option and Workspace | Aegis | Segasist P-AC 1.0 | |||
| 1. Graphical User Interface | X | No | No | ||
| 2. Motion Correction | X | No | No | ||
| 3. Tofts PK Model | X | No | No | ||
| 4. Arterial Input Function | X | No | No | ||
| 5. System Architecture | X | No | No | ||
| 6. Apparent Diffusion Coefficient (ADC) Colorized Overlay | X | No | No | ||
| 7. Contrast Arrival Detection | X | No | No | ||
| 8. Prostate Segmentation (Semi-auto Contouring) | X | No | No |
All of the added features are substantially equivalent to those in the predicate devices.
4
Summary of Technological Characteristics ર્ભ રિ
The iCAD VersaVue Enterprise Suite has the same intended use, fundamental scientific technology, and characteristics as the previously cleared predicate devices. iCAD's VersaVue Enterprise Suite and each of the predicate devices named above in Table 1 are used to process and display, in a variety of formats, the information contained in MR datasets, and provides a reliable means of visualizing MR data. DCE, other MR images and analysis results can be displayed in a variety of formats, including parametric images overlaid onto source MR images. The software also supports the analysis and presentation of data generated by the software algorithm and incorporates the following functions: Region of Interest (ROI) curve, Pixel of Interest (POI) curve, Report Card, Volume Calculation, Statistical Analysis, 3-D visualization of image series, and DICOM reporting, among other capabilities.
General Safety and Effectiveness Concerns 6.6
The device labeling contains instructions for use and any necessary cautions and warnings to provide for safe and effective use of this device. Risk management is ensured via a risk analysis, which is used to identify potential hazards. Any potential hazards are controlled via software development, verification and validation testing.
Assessment of Non-Clinical Performance Data 6.7
Validation testing was performed according to a Software System Test Plan. All performance, functional and system requirement were met. Test data was used that met the requirements to validate system performance.
6.8 Conclusion
This Special 510(k) Device Modification for the VersaVue Enterprise Suite contains adequate information and data to determine substantial equivalence to the predicate devices.
5
Image /page/5/Picture/0 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle or bird symbol, with three curved lines representing its wings and body. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" is arranged in a circular fashion around the bird symbol.
DEPARTMENT OF HEALTH & HUMAN SERVICES
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Room - WO66-G609 Silver Spring, MD 20993-0002
Michael A. Patz, MBA. RAC Senior Director, Clinical Affairs iCAD, Inc. 98 Spit Brook Road, Suite 100 NASHUA NH 03062
JUL 20 2012
Re: K121517
Trade/Device Name: VersaVue™ Enterprise Suite Regulation Number: 21 CFR 892.2050 Regulation Name: Picture archiving and communications system Regulatory Class: II Product Code: LLZ Dated: July 11, 2012 Received: July 13, 2012
Dear Mr. Patz:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of
6
medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter requirences as be form arketing your device as described in your Section 510(k) premarket will anow you to begal mained of substantial equivalence of your device to a legally marketed nonification. The I Driving of Section for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and If you decire specific da rise of Jour itro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely Yours,
Janine M. Morris
Acting Director Division of Radiological Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
7
iCAD, Inc. VersaVue Enterprise Suite
Special 510(k) Device Modification May 21, 2012
Indications for Use
510(k) Number (if known):
Device Name: VersaVue™ Enterprise Suite
Indications for Use:
The VersaVue™ Enterprise Suite consists of the MR Analysis Server software and the VersaVue Enterprise Workstation software.
The MR Analysis Server software, which includes the SpectraLook®, VividLooke and OmniLook modules is intended to be used as a post-processing software package designed to provide a reliable means for analyzing MR datasets. The software facilitates the analysis of dynamic and non-dynamic MR datasets to provide study review and additional mathematical and/or statistical analysis. The resulting analysis can be displayed in a variety of formats, including parametric images overlaid onto source MRI images.
The VersaVue Enterprise Workstation software is intended for use in conjunction with the MR Analysis Server software and facilitates the analysis and presentation of datasets generated by the MR Analysis Server software and incorporates the following functions: Region of Interest (ROI) curve, Pixel of Interest (POI) curve, Report Card, Volume Calculation, Statistical Analysis, 3-D visualization of image series, and DICOM reporting, among other capabilities.
The VersaVue Enterprise Suite serves as a workflow roadmap tool that organizes and guides the radiologist through the series of sequential tasks that must be performed in order to arrive at a diagnosis. The specific configuration of product features drives the Suite's underlying workflow solution for lesion characterization and reporting. This inherent workflow regimen integrates easily into the radiologist's existing departmental workflow and can be adapted to fit the needs of each user, thereby streamlining diagnosis. In the hands of a trained physician the information provided by the data analysis could yield information that may assist in the interpretation of dynamic and non-dynamic MR studies.
Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use AND/OR (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Division of Radiological Devices Device Evaluation and Safety 510K
Page 1 of